• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Liquidia Technologies launches Envisia Therapeutics

Liquidia Technologies launches Envisia Therapeutics

November 13, 2013
CenterWatch Staff

Envisia Therapeutics, a new biotechnology company formed by privately-held Liquidia Technologies, has launched,  backed by $25 million in Series A financing. Envisia will focus on addressing unmet medical needs in various areas of ophthalmology. Envisia’s lead product, ENV515, is an extended-release formulation of a prostaglandin analogue providing glaucoma patients a sustained reduction in intraocular pressure (IOP) over many months after single administration.

“Non-compliance continues to be a significant problem when treating patients with glaucoma. It can lead to disease progression and ultimately blindness,” said Ike Ahmed, M.D., a glaucoma specialist from the University of Toronto. “With ENV515, Envisia brings a potentially revolutionary approach to advancing glaucoma pharmacotherapy.”

In addition to ENV515, Envisia is using its proprietary PRINT(Particle Replication In Non-Wetting Templates) technology platform to create a pipeline of small and large molecule particle-based ocular therapeutics.

“Envisia and the PRINT platform have the potential to reinvent approaches to ocular therapies, radically increase product performance and, ultimately, improve patient outcomes,” said Ben Yerxa, Ph.D., chief scientific officer of Envisia.

“The success of multiple programs using the PRINT platform over the last several years has led to a wide range of opportunities in multiple therapeutic areas,” said Neal Fowler, CEO of Envisia. “With the formation and financing of Envisia, now we have the ability for both companies to optimally focus on their respective therapeutic areas—ophthalmology for Envisia, and vaccines and inhaled therapeutics for Liquidia.”

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing